Panbela Therapeutics, Inc. filed a prospectus supplement on May 15, 2024, to update and supplement information in its previous prospectus dated September 29, 2022. The supplement includes the company's quarterly report filed with the SEC on the same date. The prospectus supplement relates to the issuance of 20,100,000 shares of common stock, warrants to purchase up to 30,150,000 shares, and pre-funded warrants to purchase up to 20,100,000 shares. Panbela's common stock is quoted on the OTCQB under the symbol 'PBLA.' The last reported sales price of the common stock was $0.4408 per share as of May 14, 2024. The supplement indicates that investing in Panbela's securities involves a high degree of risk and that the SEC has not approved or disapproved the securities. The company's...Show More

Panbela Therapeutics, Inc. filed a prospectus supplement on May 15, 2024, to update and supplement information in its previous prospectus dated September 29, 2022. The supplement includes the company's quarterly report filed with the SEC on the same date. The prospectus supplement relates to the issuance of 20,100,000 shares of common stock, warrants to purchase up to 30,150,000 shares, and pre-funded warrants to purchase up to 20,100,000 shares. Panbela's common stock is quoted on the OTCQB under the symbol 'PBLA.' The last reported sales price of the common stock was $0.4408 per share as of May 14, 2024. The supplement indicates that investing in Panbela's securities involves a high degree of risk and that the SEC has not approved or disapproved the securities. The company's quarterly report reveals a net loss of $7,120,000 for the quarter ended March 31, 2024, and a decrease in cash and cash equivalents from $2,578,000 to $262,000. The report also details the company's financial statements, including balance sheets and statements of operations. Panbela Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for patients with urgent unmet medical needs, with its lead candidates being ivospemin and Flynpovi™.